ENTRADA THERAPEUTICS INC shares fell more than 50% after its Duchenne muscular dystrophy drug failed to meet analyst efficacy targets. The trial reported a 2.36 percentage point increase in dystrophin protein from a 4% baseline, trailing the 10% minimum threshold set by William Blair analysts. This clinical shortfall places Entrada behind competitors in the race for exon-44 skipping treatments.

Trial Data Misses the Competitive Bar